Membrane-permeable NFAT inhibitory peptide
View Patent ↗The present invention aims to solve the conventional problems by providing a peptide compound, in which when administered to a patient of immunologic disease, cardiac hypertrophy or a disease caused by NFAT activation, the period from administration to actual exhibition of effectiveness is short and there are no side effects or antigenicity. Specifically, the present invention relates to a membrane permeable NFAT inhibitory peptide comprising several consecutive arginines and a NFAT-activity inhibitory peptide sequence; a NFAT activation inhibitory agent comprising the peptide; and a immunosuppressive agent and cardiac hypertrophy suppressive agent, comprising the peptide compound as the active ingredient.
1. A therapeutic method, comprising the step of:
administering a peptide compound comprising 9 to 13 residues of arginine and the amino acid sequence of SEQ ID NO: 1, to a patient at a level that produces immunosuppression in the patient.
2. The therapeutic method of claim 1 , wherein said peptide compound comprises 11 residues of arginine.
3. The therapeutic method of claim 1 , wherein the compound is administered at a dosage in the range of 1 to 10 mg/kg.
4. The therapeutic method of claim 2 , wherein the compound is administered at a dosage in the range of 1 to 10 mg/kg.
5. A therapeutic method, comprising the step of:
administering a peptide compound comprising 9 to 13 residues of arginine and the amino acid sequence of SEQ ID NO: 1, to a patient at a level that suppresses cardiac hypertrophy in the patient.
6. The therapeutic method of claim 1 , wherein said peptide comprises 11 residues of arginine.
7. The therapeutic method of claim 5 , wherein the compound is administered at a dosage in the range of 0.1 to 2 mg/kg.
8. The therapeutic method of claim 6 , wherein the compound is administered at a dosage in the range of 0.1 to 2 mg/kg.